Pant S - Search Results

1

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN. Bendell JC, et al. Among authors: pant s. Clin Cancer Res. 2018 Jul 15;24(14):3253-3262. doi: 10.1158/1078-0432.CCR-17-3421. Epub 2018 Apr 10. Clin Cancer Res. 2018. PMID: 29636360 Clinical Trial.

2

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.

Pant S, Burris HA 3rd, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. Pant S, et al. Invest New Drugs. 2014 Feb;32(1):87-93. doi: 10.1007/s10637-013-9949-4. Epub 2013 Mar 24. Invest New Drugs. 2014. PMID: 23525756 Free PMC article. Clinical Trial.

3

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.

Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Pant S, et al. Cancer. 2014 Jun 15;120(12):1780-6. doi: 10.1002/cncr.28648. Epub 2014 Mar 13. Cancer. 2014. PMID: 24633933 Free PMC article. Clinical Trial.

4

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH. Pant S, et al. Ann Oncol. 2014 Jul;25(7):1416-1421. doi: 10.1093/annonc/mdu157. Epub 2014 Apr 15. Ann Oncol. 2014. PMID: 24737778 Free article. Clinical Trial.

5

Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.

Bendell JC, Patel MR, Infante JR, Kurkjian CD, Jones SF, Pant S, Burris HA 3rd, Moreno O, Esquibel V, Levin W, Moore KN. Bendell JC, et al. Among authors: pant s. Cancer. 2015 Apr 1;121(7):1056-63. doi: 10.1002/cncr.29155. Epub 2014 Nov 19. Cancer. 2015. PMID: 25411085 Free PMC article. Clinical Trial.

6

A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.

Bendell JC, Jones SF, Hart L, Pant S, Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, Thompson D, Infante JR. Bendell JC, et al. Among authors: pant s. Cancer Invest. 2015;33(10):477-82. doi: 10.3109/07357907.2015.1069834. Epub 2015 Oct 13. Cancer Invest. 2015. PMID: 26460795 Clinical Trial.

7

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.

Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BKR, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ESM, Chan EM, Bendell JC. Pant S, et al. Eur J Cancer. 2016 Mar;56:1-9. doi: 10.1016/j.ejca.2015.11.021. Epub 2016 Jan 19. Eur J Cancer. 2016. PMID: 26798966 Free article. Clinical Trial.

8

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.

Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT. Bendell JC, et al. Among authors: pant s. Cancer Chemother Pharmacol. 2016 Jun;77(6):1275-83. doi: 10.1007/s00280-016-3031-9. Epub 2016 May 5. Cancer Chemother Pharmacol. 2016. PMID: 27151157 Free PMC article. Clinical Trial.

9

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Naing A, et al. Among authors: pant s. J Clin Oncol. 2016 Oct 10;34(29):3562-3569. doi: 10.1200/JCO.2016.68.1106. J Clin Oncol. 2016. PMID: 27528724 Free PMC article. Clinical Trial.

10

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.

Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Sarantopoulos J, et al. Among authors: pant s. Cancer Chemother Pharmacol. 2016 Nov;78(5):921-927. doi: 10.1007/s00280-016-3122-7. Epub 2016 Sep 28. Cancer Chemother Pharmacol. 2016. PMID: 27681579 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

767 results

Search Page

Filters